Factors Affecting the Development of Cardiovascular Events Among Patients with End-Stage Renal Disease Undergoing Hemodialysis in Sudan

Year 2017, Volume: 1 Issue: 3, 61 - 65, 01.09.2017

Omalhassan Amir Azmi Sarriff Mohamed Babikir Abdelraheem Amer Hayat Khan Bachok Norsa’adah

https://doi.org/10.5152/jbachs.2017.144

Abstract

Purpose: This study aimed to determine factors that affected the development of new onset cardiovascular events among patients with end-stage renal disease ESRD undergoing hemodialysis HD at the Khartoum HD centers in Sudan.Methods: A prospective observational study was conducted among anemic ESRDpatients undergoing HD at Khartoum State HD centers. A total of 1015 patients undergoing HD were recruited from 12 HD centers. A standardized data collection form was used for collecting the required data. Logistic regression analysis was performed.Results: Of 1015 recruited patients, 534 52.6% were included in the final analysis; the 481 patients who were excluded comprised 194 19.1% patients who were transferred to other centers, 165 16.3% who died, 84 8.3% who were lost during follow-up, and 38 3.7% who underwent renal transplantation. The significant factors that affected the development of new cardiovascular events in 154 28.8% anemic ESRD patients were advanced age [for patients aged 45-64 years: odds ratio OR , 1.94; 95% confidence interval CI , 1.18-3.18; p=0.009 and for patients aged ≥65 years: OR, 10.88; 95% CI, 6.12-19.33; p

Keywords

End-stage renal disease, anemia, hemodialysis, cardiovascular events, risk factors, Sudan

References

• National Kidney Foundation, K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000. Am J Kidney Dis 2001; 37:182-238. [CrossRef]
• Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia manage- ment and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2004; 44:94-111. [CrossRef]
• Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4:33-38. [CrossRef]
• Borghi, L, Meschi T, Guerra A, Briganti A, Schianchi T, Allegri F. He- moglobin variability in nondialysis chronic kidney disease: exam- ining the association with mortality. Clin J Am Soc Nephrol 2009; 4:1176-1182. [CrossRef]
• Anderson G, Steinberg EP, Whittle J, Powe NR, Antebi S, Herbert R. Development of clinical and economic prognoses from Medicare claims data. JAMA 1990; 263:967-972. [CrossRef]
• Wilson PW, D’agostino RB, Levy D, Belanger AM, Silbershatz H, Kan- nel WB. Prediction of coronary heart disease using risk factor cate- gories. Circulation J 1998; 97:1837-1847. [CrossRef]
• Sarnak MJ, Levey AS. Cardiovascular disease and chronic re- nal disease: a new paradigm. Am J Kidney Dis 2000; 35:117-131. [CrossRef]
• Sliwa K, Wilkinson D, Hansen C, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet J 2008; 371:915-922. [CrossRef]
• Silva LS, Oliveira RA, Silva GB, et al. Cardiovascular disease in pa- tients with end-stage renal disease on hemodialysis in a develop- ing country. Saudi J Kidney Dis Transpl 2012; 23:262-266.
• Li S, Foley R, Collins A. Anemia and cardiovascular disease, hos- pitalization,end stage renal disease, and death in older patients with chronic kidney disease. Geriatr Nephrol Urol 2005; 37:395-402. [CrossRef]
• Charlton KE, Steyn K, Levitt NS, et al. Diet and blood pressure in South Africa: Intake of foods containing sodium, potassium, calcium, and magnesium in three ethnic groups. Nutrition J 2005; 21:39-50. [CrossRef]
• Mensah GA. Ischaemic heart disease in Africa. Heart 2008; 94:836- 843. [CrossRef]
• Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovas- cular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008; 4:672-681. [CrossRef]
• Census. The 5th Sudan population and housing census-2008, prior- ity results 2009; Population Census Council, 2008.
• Dupont W, Plummer W. PS power and sample size program avail- able for free on the internet. Controlled Clin Trials 1997-2009. Version 3.1.2.
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N & Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. [CrossRef]
• World Health Organization. Global data on Body mass index, Body mass index (BMI) classification. World Health Organization 2006 [cited 23 March 2014; Available from: http://apps.who.int/bmi/in- dex.jsp?introPage=intro_3.html.
• Kidney Disease, Improving Global Outcomes (KDIGO) Anemia Work Group. KIDGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2:279-335.
• Field A. Discovering statistics using SPSS. 2nd ed. London: SAGE Publications LTD; 2005.
• Tong J, Liu M, Li H, et al. Mortality and Associated Risk Factors in Dialysis Patients with Cardiovascular Disease. Kidney Blood Press Res 2016; 41:479-487. [CrossRef]
• USRDS. USRDS Annual Data Report: Epidemiology of Kidney Dis- ease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2015; [Accessed 20 March 2016]; Available from: https:// www.usrds.org/2015/view/v2_06.aspx.
• Banaga AS, Mohammed EB, Siddig RM, et al. Causes of end stage renal failure among haemodialysis patients in Khartoum State/Su- dan. BMC Res Notes 2015; 8:502. [CrossRef]
• Khalil SI. Cardiovascular disease in Sudan: Past, present and future prospects. Sudan Heart J 2013; 1.
• Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308:2349-2360. [CrossRef]
• Yilmaz FM, Yilmaz G, Duranay M, et al. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Scand J Clin Lab Invest Suppl 2005; 65:739-745. [CrossRef]
• Singh AK, Szczech L, Tang KL, et al. Correction of Anemia with Epo- etin Alfa in Chronic Kidney Disease (CHIOR). N Engl J Med 2006; 355:2085-2098. [CrossRef]
• Rule AD, Bergstralh EJ, Melton LJ, Li X, Weaver AL, Lieske JC. Kid- ney Stones and the Risk for Chronic Kidney Disease. Clin J Am Soc Nephrol 2009; 4:804-811. [CrossRef]
• Elsharif M, Elsharif E. Causes of end-stage renal disease in Sudan: a single-center experience. Saudi J Kidney Dis Transpl 2011; 22:373-6.
• Ferraro PM, Taylor EN, Eisner BH, et al. History of kidney stones and the risk of coronary heart disease JAMA 2013; 310:408-415. [CrossRef]
• Liu Y, Li S, Zeng Z, et al. Kidney stones and cardiovascular risk:A Meta analysis of Cohort Studies. Am J Kidney Dis 2014; 64:402-410. [CrossRef]
• Glover LM, Bass MA, Carithers T, et al. Association of kidney stones with atherosclerotic cardiovascular disease among adults in the United States: Considerations by race-ethnicity. Physiol. Behav 2016; 157:63-66. [CrossRef]
• Reiner AP, Kahn A, Eisner BH, et al. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J Urol 2011; 185:920-925. [CrossRef]
• Lomashvili KA, Narisawa S, Millán JL. Vascular calcification is dependent on plasma levels of pyrophosphate. Kidney Int 2014; 85:1351-1356. [CrossRef]
• Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovas- cular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005; 1:183-198.
• Madore F, Stampfer MJ, Willett WC, Speizer FE & Curhan GC. Neph- rolithiasis and risk of hypertension in women. Am J Kidney Dis 1998; 32:802-807. [CrossRef]
• Borghi L, Meschi T, Guerra A, et al. Essential arterial hypertension and stone disease. Kidney Int 1999; 55:2397-406. [CrossRef]
• Domingos F, Serra A. Nephrolithiasis is associated with an in- creased prevalence of cardiovascular disease. Nephrol Dial Trans- plant 2011; 26:864-868. [CrossRef]